Skip to main content
BMC Gastroenterology logoLink to BMC Gastroenterology
. 2023 Feb 2;23:31. doi: 10.1186/s12876-022-02636-9

Correction: Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn’s disease: a multicentre retrospective study

Cassandra Rayer 1, Maria Nachury 2, Arnaud Bourreille 3, Xavier Roblin 4, Laurent Peyrin-Biroulet 5, Stephanie Viennot 6, Mathurin Flamant 7, David Laharie 8, Bénédicte Caron 5, Marie Dewitte 1, Laurent Siproudhis 9, Mathurin Fumery 10, Guillaume Bouguen 9,11,
PMCID: PMC9896746  PMID: 36732693

Correction to: BMC Gastroenterology (2022) 22:498 10.1186/s12876-022-02583-5

After publication of this article [1], the authors reported that the given and family names of most authors were incorrectly structured. The correct list of authors is: Cassandra Rayer, Maria Nachury, Arnaud Bourreille, Xavier Roblin, Laurent Peyrin-Biroulet, Stephanie Viennot, Mathurin Flamant, David Laharie, Bénédicte Caron, Marie Dewitte, Laurent Siproudhis, Mathurin Fumery and Guillaume Bouguen.

The original article [1] has been corrected.

Footnotes

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Reference

  • 1.Rayer C, Nachury M, Bourreille A, Roblin X, Peyrin-Biroulet L, Viennot S, Flamant M, Laharie D, Caron B, Dewitte M, Siproudhis L, Fumery M, Bouguen G. Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn’s disease: a multicentre retrospective study. BMC Gastroenterol. 2022;22:498. doi: 10.1186/s12876-022-02583-5. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from BMC Gastroenterology are provided here courtesy of BMC

RESOURCES